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grade fever of 2 months’ duration. His
past medical history was unremark-
able, except for pulmonary tuberculo-
sis treated 55 years earlier and chronic
glaucoma. He lived in a rural area and
had rare contact with cattle. On admis-
sion, his body temperature was
39.5°C; his right laterocervical lymph
nodes were enlarged (3 cm x 4 cm)
and inflamed. Blood values were unre-
markable except for an elevated C-
reactive protein level of 150 mg/L
(normal<6). A computed tomography
scan of the chest showed hilar calcifi-
cations and enlarged mediastinal
lymph nodes. A biopsy of cervical
lymph nodes indicated granulomatous
lymphadenitis with foci of necrosis. C.
burnetii DNA was detected on the
lymph nodes with a C. burnetii–spe-
cific pair of primers that amplified an
htpAB-associated repetitive element
(6). Results of serologic testing by
indirect immunofluorescence (IF)
were positive for C. burnetii with
immunoglobulin (Ig) G antibody titer
to phase 1 and phase 2 antigen of 800
and 1,600, respectively, and IgM anti-
body titer to phase 2 antigen of 50. 
A 44-year-old man was admitted
to the hospital because of a continuous
low-grade fever of 3 months’ duration.
He had worked as a farmer for 15
years and assisted in the birth of sheep
and cattle. On admission, his body
temperature was 38°C, and right
inguinal lymph nodes were inflamed,
measuring 4 x 4 cm. A lymph node
biopsy showed granulomatous lym-
phadenitis with stellate abscesses sur-
rounded by palisading epithelioid
cells. Serologic testing by indirect IF
was positive for C. burnetii with an
IgG antibody titer to phase 1 antigen
of 320. 
For both patients, results of Ziehl
staining and Lowenstein (Bio-Rad,
Marne-La-Coquette, France)  cultures
of gastric aspirates (x 3) and lymph
node specimens  were negative for
mycobaceria,  as were the results of
tuberculin skin tests. Other diseases
were ruled out, including brucellosis,
yersiniosis, bartonellosis, and chlamy-
dial infections (by serologic testing)
and fungal infections (parasitologic
studies on lymph node tissue). Antinu-
clear antibodies were absent, and
angiotensin-converting-enzyme val-
ues were normal. Both patients
received doxycycline, 200 mg once a
day, and rifampin, 600 mg twice a day,
for 1 year, and the symptoms resolved
(follow-up at 18 months for patient 1
and 9 months for patient 2, respec-
tively). For patient 1, serologic testing
after 1 year of treatment showed an
IgG antibody titer to phase 1 antigen
of 320.
Granulomatous lymphadenitis has
been described during mycobacterial
infections, tularemia, cat scratch dis-
ease, yersiniosis, lymphogranuloma
venereum, histoplasmosis, coccidio-
idomycosis, and chronic granuloma-
tous diseases (7). One well-
documented case of acute Q fever
with necrotic cervical lymphadenitis
has been recently reported (8); to our
knowledge, granulomatous lymphad-
enitis has never been reported during
Q fever. In both cases reported here,
C. burnetii was the likely etiologic
agent, given the results of polymerase
chain reaction and serologic studies
(patient 1) or the patient’s occupation
and results of the serologic testing
(patient 2). Moreover, for both, no
other potential cause could be identi-
fied, and the response to doxycycline-
rifampin regimen was favorable. We
suggest that granulomatous lymphad-
enitis be added to the list of atypical
presentations of Q fever.
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Has Coxiella 
burnetii (Q fever) 
Been Introduced 
into New Zealand?
To the Editor: New Zealand has
been an exception to the panglobal
distribution of Coxiella burnetii (1),
the causative organism of Q fever, as
shown in a 1990–1991 study (2) of
12,556 sheepdogs and 2,181 aborting
cattle, all seronegative for C. burnetii.
In 1997, the Rabbit hemorrhagic dis-
ease virus (RHDV) was illegally
imported from Australia into Central
Otago, New Zealand, for the purpose
of rabbit control. The unknown source
and purity of RHDV, and the potential
use of infected rabbits or their organs
to transport it, meant that C. burnetii
could have been coincidentally intro-
duced along with the RHDV-infected
rabbit material. To establish whether
this occurred, we examined serumEmerging Infectious Diseases  •  Vol. 9, No. 1, January 2003 139
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specimens from 97 participants
enrolled in the RHDV human health
study for antibodies to Q fever (3). 
C. burnetii is a very infective
organism; it can remain viable for
long periods in harsh environmental
conditions (1). The primary route of
human exposure is aerosol dispersion
(1), and airborne agricultural dusts
containing the organism have been
implicated in the infection of distant
communities (4). 
Wild rabbits are part of the exten-
sive reservoir of C. burnetii in the ani-
mal kingdom (1) and have been linked
with Q fever (5). In the United States,
53% of wild rabbits and 39% of wild
jackrabbits were found to have anti-
bodies to C. burnetii, and the organ-
ism has been isolated from both these
species (6); in Nova Scotia, 49% of
hares had antibodies to C. burnetii (7).
In Australia, Q fever is estimated to
result in at least 1,700 weeks of lost
work time annually, primarily affect-
ing people in the eastern states (8).
We could not find evidence of C.
burnetii in Australian rabbits despite
the frequency of Q fever in that coun-
try (8) and reports of extensive C. bur-
netii  infection of rabbits in other
countries (6). However, the presence
of RHDV-infected rabbits in the part
of Australia where Q fever is most
often reported (8,9) suggested that the
rabbit tissue imported to New Zealand
in 1997 might have been infected with
C. burnetii. 
A local lawyer enrolled the study
participants anonymously on the
basis of their possible exposure to the
illegally imported rabbit material.
These participants provided serum
samples and answered interviewer-
administered questionnaires 15 weeks
after the first confirmation of the
virus (3). As a result of the contro-
versy and potential legal proceedings
surrounding the circumstances of the
biosecurity breach, several questions
were considered too sensitive and
were not asked; these included the
participants’ travel history and exact
details of their roles in processing the
infected rabbit material. However, in
many cases the participants volun-
teered additional information regard-
ing their exposures.
Nearly all participants (86/97) had
had contact with rabbits, and more
than half (53/97) appeared to have had
contact with RHDV-infected rabbit
material. Anecdotal reports suggest
that heavy exposures occurred during
the harvesting and processing of
infected rabbit body organs, spraying
of infective organ mixtures onto bait,
and distribution of these infective
baits by air and ground over 136,000
hectares (340,000 acres).
Thirteen persons were considered
to have had a variety of inhalation
exposures. Four persons mentioned
tasting, smelling, breathing, or having
the spray blown in their face for 3–5
hours; another four participants
referred to their involvement in spray-
ing. Another four participants had
concerns about their inhalation expo-
sures, and one person was included on
the basis of exposure while shoveling
carrots mixed with infected rabbit
blood and molasses. Many additional
aerosol exposures likely occurred that
the researchers could not specifically
identify.
Of the 97 serum samples, 3 were
classified as positive to C. burnetii, 1
as equivocal, and 93 as negative by
using an enzyme-linked immunosor-
bent assay (PanBio IgG Cat No QFG
100, Brisbane, Australia). On the basis
of a single test, determining how many
of the results were false positive is dif-
ficult: an assay specificity estimate of
95.7% (10) suggests we might expect
to correctly identify 93 negative serum
samples in a population of 97 with no
exposure to Q fever. 
No evidence of an association
between seropositivity and exposure
to infective rabbit material was appar-
ent. The most strongly positive result
was found in a person who had
described no major exposures. One
positive result occurred among 39 per-
sons with possible direct contact (i.e.,
open wound) exposure, and another
among 17 persons who had eaten pos-
sibly infected rabbit material. None of
the 13 persons with inhalation expo-
sures, the 2 persons with needlestick
injuries, or the 1 person with a definite
bait consumption exposure had serum
samples that were positive or equivo-
cal. Likewise, none of the seven per-
sons with reported health problems
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had serum samples that were either
positive or equivocal. The low preva-
lence of antibodies to C. burnetii in
the participants in our study (3/97)
indicates that most were very unlikely
to have had contact with the organism.
If the results are true positives, the
source of the infection was quite likely
outside of New Zealand. However,
considering the heavy exposures asso-
ciated with the cultivation and har-
vesting of RHDV in live rabbits and
the known infectivity of Q fever, C.
burnetii was not likely to have been
introduced inadvertently to New
Zealand at the same time as RHDV. 
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Correction, Vol.8, No.12
In the article, “Antimicrobial Resistance of Escherichia coli
O26, O103, O111, O128, and O145 from Animals and Humans” by
Carl M. Schroeder et al., errors occurred in the figure on page 1412.
The corrected figure appears below and online at http://
www.cdc.gov/ncidod/eid/vol8no12/02-0070.htm. 
We regret any confusion these errors may have caused.
Figure 2. Comparison of antimicrobial resistance frequencies
between Shiga toxin–producing Escherichia coli (STEC) and other
E. coli. Of isolates from cattle, resistance frequencies were similar
between STEC and other E. coli (A). In contrast, of isolates from
humans, resistance frequencies were generally lower for STEC com-
pared with other E. coli (B). Am, ampicillin; Cx, cefoxitin; C,
chloramphenicol; Frx, ceftriaxone; Smx, sulfamethoxazole; Cf,
cephalothin; Gm, gentamicin; NA, nalidixic acid; Cip, ciprofloxacin;
Fur, ceftiofur; Te, tetracycline; T/S, trimethoprim-sulfamethoxazole;
A/C, amoxicillin-clavulanic acid; Str, streptomycin.
Correction, Vol. 8, No. 10
In “Investigation of Bioterrorism-Related Anthrax,
United States, 2001: Epidemiologic Findings” by Daniel B.
Jernigan et al., errors occurred in the listing of the members
of the Anthrax Epidemiologic Investigation Team on page
1019. Additional members of the National Anthrax Epide-
miologic Investigation Team are:
Francisco Alvarado-Ramy, MacKenzie Andre,
MaryKate Appicelli, Mick Ballesteros, Mark Beatty, Omo-
tayo Bolu, Louise Causer, Soju Chang, Ilin Chuang, John
Crump, Marvin DeBerry, Rachel Gorwitz, Michelle
Goveia, Thomas Handzel, Josh Harney, Dan Hewett, Vin-
cent Hsu, Young Hur, Marialena Jefferds, Joshua Jones,
Kathleen Julian, Richard Kanwal, Jane Kelly, Dennis Kim,
Judy Kruger, Richard Leman, Steve Lenhart, Jill Levine,
Naile Malakmadze, Els Mathieu, Rob McCleery, Shawn
McMahon, Manoj Menon, Kelly Moore, Jill Morris, James
Andy Mullins, Melanie Myers, Timothy Naimi, Lori New-
man, Chima John Ohuabunwao, Michael O'Reilly, Lisa
Pealer, Chris Piacitelli, Joe Posid, John Redd, Mary Rey-
nolds, Julia Rhodes, Louie Rosencrans, Lisa Roth, Denise
Roth-Allen, Sharon Roy, Taraz Samandari, Dejana Selenic-
Stanacev, Jina Shah, Tanya Sharp, Allison Stock, Laura-
lynn Taylor, Pauline Terebuh, Christopher Thomas, Beth
Tohill, Barna Tugwell, Angela Weber, Dana White, Sara
Whitehead, Wally Wilhoite, Leigh Winston, Brad Winter-
ton, Katharine Witgert, William Wong, Susie Wootton, and
Weigong Zhou
We regret any confusion these errors may have caused.